Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis

Scandinavian Journal of Gastroenterology

Volumn 52, Issue 9, 2017, Pages 1022-1028

  Danielsson Borssén, Åsa ^a   Marschall, Hanns Ulrich ^b   Bergquist, Annika ^c   Rorsman, Fredrik ^d   Weiland, Ola ^c   Kechagias, Stergios ^e,f   Nyhlin, Nils ^g   Verbaan, Hans ^h   Nilsson, Emma ⁱ   Werner, Mårten ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g Örebro University   (Sweden)

^h LUND UNIVERSITY   (Sweden)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autoimmune hepatitis; causes of death; cirrhosis; epidemiology; liver

Indexed keywords

CORTICOSTEROID; MERCAPTOPURINE;

ABDOMINAL PAIN; ACCIDENT; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHILD; CHOLANGITIS; CLINICAL OBSERVATION; COHORT ANALYSIS; COLITIS; CORTICOSTEROID THERAPY; DEMENTIA; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HUMAN; ILEUS; INCIDENCE; INFECTION; INTOXICATION; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIMARY BILIARY CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SUICIDE; SURVIVAL; SURVIVAL ANALYSIS; SWEDEN; SWEDISH CITIZEN; TRANSPLANTATION FREE SURVIVAL; UNIVERSITY HOSPITAL; VARICOSIS; VERY ELDERLY; AGE DISTRIBUTION; COMPLICATION; EPIDEMIOLOGY; INFANT; MORTALITY; NEWBORN; PRESCHOOL CHILD; REGISTER; RETROSPECTIVE STUDY; SEX RATIO; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SWEDEN; YOUNG ADULT;

EID: 85020075816     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2017.1335772     Document Type: Article

References (27)

1. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis:a disease of older women?. J Gastroenterol Hepatol. 2010;25:1681–1686.
2. Amarapurkar DN, Patel ND., Spectrum of autoimmune liver diseases in western India. J Gastroenterol Hepatol. 2007;22:2112–2117.
3. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–2407.
4. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden:a nationwide study. Scand J Gastroenterol. 2008;43:1232–1240.
5. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.
6. Gronbaek L, Vilstrup H, Jepsen P., Autoimmune hepatitis in Denmark:incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612–617.
7. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease:a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.
8. Murray-Lyon IM, Stern RB, Williams R., Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737.
9. Cook GC, Mulligan R, Sherlock S., Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185.
10. Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45:457–467.
11. Roberts SK, Therneau TM, Czaja AJ., Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848–857.
12. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis:effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.
13. Delgado JS, Vodonos A, Malnick S, et al. Autoimmune hepatitis in southern Israel:a 15-year multicenter study. J Dig Dis. 2013;14:611–618.
14. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980–1989.
15. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report:review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.
16. Duberg A, Janzon R, Back E, et al. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill. 2008;13.
17. Dödsorsaksstatistik Historik, produktionsmetoder och tillförlitlighet [Internet]. Welfare TNBoHa, editor. The National Board of Health and Welfare; 2010 [cited 2016 Dec 11]. p. 38. Available from:http://www.socialstyrelsen.se
18. Causes of Death 2010. The National Board of Health and Welfare; [Internet]. 2011 [cited 2016 Dec 11]. Available from:http://www.socialstyrelsen.se
19. Befolkning (Population). Statistics Sweden; [Internet]. 2011 [cited 2016 Dec 27]. Available from:http://www.scb.se/statistik/_publikationer/ov0904_2011a01_br_05_a01br1101.pdf
20. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49:1245–1254.
21. Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008;48:140–147.
22. Ngu JH, Gearry RB, Frampton CM, et al. Predictors of poor outcome in patients with autoimmune hepatitis:a population-based study. Hepatology. 2013;57:2399–2406.
23. Czaja AJ, Donaldson PT., Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051–2057.
24. Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis:clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051–1057.
25. Kanzler S, Lohr H, Gerken G, et al. Long-term management and prognosis of autoimmune hepatitis (AIH):a single center experience. Z Gastroenterol. 2001;39:339–341, 44–48.
26. Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology. 2012;56:668–676.
27. Montano-Loza AJ, Carpenter HA, Czaja AJ., Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007;27:507–515.